Not all patients respond well to chimeric antigen receptor (CAR) T cell therapies, which reprogram a patient’s own immune cells to recognize and attack cancer. A way to optimize these treatments is to ...

Much of what biologists know about the human immune system has been — quite literally — illuminated by flow cytometry. For more than 70 years, this technology has evolved to become one of immunology’s ...

CAR-T translational research demands precise, reproducible, and scalable flow cytometry workflows. Manual centrifugation and antibody preparation steps remain major sources of variability and cell ...

CHICAGO — Rosnilimab, a novel pathogenic T-cell depleting drug, met its primary endpoint of changes in DAS28 C-reactive ...

Of the 11 patients treated with BE-CAR7 T cells, seven are in remission, including one patient who has been in remission for three years.

Elevated PD-1+CD4+ T cells represent an independent risk factor for lupus nephritis (LN) and may serve as a biologically meaningful diagnostic and therapeutic target.

By Priyanjana Pramanik, MSc. Even when immune memory cells form in the lung after influenza infection, insufficient dietary ...